PURPOSE: Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in human bladder cancer, but its role in breast cancer is controversial. MATERIALS AND METHODS: We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancer patients by using proteomic approaches. RESULTS: By using a proteomic approach, we observed an increased expression of RhoGDI2 in human breast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancer patients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancer patients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15). CONCLUSION: Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.
PURPOSE: Recent research has identified many genes and proteins that play specific roles in the process of systemic metastasis in various types of cancer. Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to inhibit metastasis in humanbladder cancer, but its role in breast cancer is controversial. MATERIALS AND METHODS: We examined the regulation and clinical significance of RhoGDI2 in Korean breast cancerpatients by using proteomic approaches. RESULTS: By using a proteomic approach, we observed an increased expression of RhoGDI2 in humanbreast cancer tissues when compared to that of the normal breast tissues, and we validated its up-regulation in an independent cohort of 8 breast cancerpatients. The clinical implication of a RhoGDI2 expression was investigated in 57 breast cancerpatients by performing immunohistochemistry. RhoGDI2 did not show a significant association with the tumor size, lymph node metastasis, the histologic grade or the hormone receptor status. However, the patients with RhoGDI2-expressing tumors had significantly shorter disease-free survival (p=0.043; hazard ratio, 3.87) and distant metastasis-free survival (p=0.039; hazard ratio, 5.15). CONCLUSION: Our results demonstrated a potential role of RhoGDI2 as a poor prognostic marker as well as a potential therapeutic target. The pro-metastatic nature of RhoGDI2 shown in our study may indicate its organ-specific role in cancer metastasis.
Entities:
Keywords:
Breast neoplasms; Neoplasm metastasis; Prognosis; Proteomics; RhoGDI2 protein
Authors: B Bouzahzah; C Albanese; F Ahmed; F Pixley; M P Lisanti; J D Segall; J Condeelis; D Joyce; A Minden; C J Der; A Chan; M Symons; R G Pestell Journal: Mol Med Date: 2001-12 Impact factor: 6.354
Authors: H Leffers; M S Nielsen; A H Andersen; B Honoré; P Madsen; J Vandekerckhove; J E Celis Journal: Exp Cell Res Date: 1993-12 Impact factor: 3.905
Authors: John J Gildea; M Jabed Seraj; Gary Oxford; Michael A Harding; Garret M Hampton; Christopher A Moskaluk; Henry F Frierson; Mark R Conaway; Dan Theodorescu Journal: Cancer Res Date: 2002-11-15 Impact factor: 12.701
Authors: A Yokoyama; J Okabe-Kado; N Wakimoto; H Kobayashi; A Sakashita; N Maseki; T Nakamaki; K i Hino; S Tomoyasu; N Tsuruoka; K Motoyoshi; N Nagata; Y Honma Journal: Blood Date: 1998-03-15 Impact factor: 22.113
Authors: Dan Theodorescu; L M Sapinoso; M R Conaway; G Oxford; G M Hampton; H F Frierson Journal: Clin Cancer Res Date: 2004-06-01 Impact factor: 12.531
Authors: A Leone; R C Seeger; C M Hong; Y Y Hu; M J Arboleda; G M Brodeur; D Stram; D J Slamon; P S Steeg Journal: Oncogene Date: 1993-04 Impact factor: 9.867
Authors: Wen G Jiang; Gareth Watkins; Jane Lane; Giles H Cunnick; Anthony Douglas-Jones; Kefah Mokbel; Robert E Mansel Journal: Clin Cancer Res Date: 2003-12-15 Impact factor: 12.531
Authors: Jonathan Hensel; Jason E Duex; Charles Owens; Garrett M Dancik; Michael G Edwards; Henry F Frierson; Dan Theodorescu Journal: Mol Cancer Res Date: 2015-06-15 Impact factor: 5.852
Authors: T Qayyum; G Fyffe; M Duncan; P A McArdle; M Hilmy; C Orange; G Halbert; M Seywright; P G Horgan; M A Underwood; J Edwards Journal: Br J Cancer Date: 2012-02-21 Impact factor: 7.640
Authors: Stefan Steurer; Benjamin Hager; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Sarah Minner; Till S Clauditz; Claudia Hube-Magg; Andreas M Luebke; Ronald Simon; Jakob R Izbicki; Eike Burandt; Guido Sauter; Christoph Fraune; Sören Weidemann; Thorsten Schlomm; Hans Heinzer; Alexander Haese; Markus Graefen; Hartwig Huland; Asmus Heumann Journal: Aging (Albany NY) Date: 2019-09-25 Impact factor: 5.682